Table 4.
Plasma protein profiles at study onset and at completion
| No. | TNF-α and soluble receptors |
Proinflammatory cytokines |
T-cell cytokines |
|||||
|---|---|---|---|---|---|---|---|---|
| TNF-α, pg/mL | TNFRI, pg/mL | TNFRII, pg/mL | IL-6, pg/mL | IL-1β, pg/mL | IL-2, pg/mL | INF-γ, pg/mL | ||
| Control (NL) | 7 | 2.2 ± 2.2 | 999 ± 198 | 1722 ± 303 | 2.3 ± 0.4 | LOD | ND | 1.0 ± 1.0 |
| Control (BMT) | 9 | 18.3 ± 4.5 | 1489 ± 204 | 4275 ± 604 | 7.3 ± 2.1 | LOD | ND | ND |
| IPS-PreHCT | 12 | 16.2 ± 3.6 | 2043 ± 382 | 3415 ± 412 | 6.9 ± 1.5 | LOD | ND | 0.9 ± 0.6 |
| IPS-Dx (All) | 14 | 63 ± 12* | 6257 ± 1100* | 15 543 ± 4137* | 856 ± 460* | LOD | ND | 43.8 ± 23.1 |
| IPS-Dx (NR) | 5 | 60 ± 17 | 9058 ± 2645 | 27 267 ± 9670 | 947 ± 822 | LOD | ND | 32 ± 12 |
| IPS-Dx (Resp) | 9 | 71 ± 19 | 4949 ± 515 | 9030 ± 1560 | 906 ± 557 | LOD | ND | 49 ± 34 |
| IPS-post (Resp) | 9 | 119 ± 45 | 3000 ± 528‖ | 88 508 ± 20 541‖ | 152 ± 60§ | LOD | ND | 5.5 ± 5.1 |
| LPS activation cascade |
Anti-inflammatory cytokines |
Proinflammatory chemokines |
||||||
| sCD14, ng/mL | LBP, ng/mL | IL-1ra, pg/mL | TGF-β, pg/mL | IL-8, pg/mL | CCL2, pg/mL | CXCL9, pg/mL | ||
| Control (NL) | 7 | 1501 ± 311 | 20 437 ± 961 | 133 ± 32 | 1046 ± 547 | 6.4 ± 0.8 | 386 ± 46 | ND |
| Control (BMT) | 9 | 2414 ± 103 | 30 768 ± 3188 | ND | 1178 ± 241 | 23.7 ± 4.9 | 357 ± 65 | 165 ± 12.4 |
| IPS-Pre HCT | 12 | 1925 ± 303 | 19 754 ± 303 | ND | 2530 ± 735 | 18.5 ± 3.6 | 348 ± 87 | 264 ± 57 |
| IPS-Dx (All) | 14 | 3415 ± 551† | 93 353 ± 22 723* | 874 ± 192† | 2306 ± 492‡ | 1008 ± 333* | 3317 ± 1265* | 1479 ± 725* |
| IPS-Dx (NR) | 5 | 4799 ± 1360 | 62 353 ± 11 330 | 1130 ± 375 | 2723 ± 992 | 531 ± 340 | 895 ± 407 | 1087 ± 435 |
| IPS-Dx (Resp) | 9 | 2723 ± 338 | 110 575 ± 34 144 | 721 ± 246 | 1700 ± 475 | 1430 ± 540 | 5323 ± 2100 | 2020 ± 1432 |
| IPS-post (Resp) | 9 | 1661 ± 269‖ | 17 836 ± 2558‖ | 455 ± 155 | 1435 ± 615 | 549 ± 209 | 1670 ± 994§ | 455 ± 137 |
Plasma samples were collected and plasma protein levels analyzed from all IPS patients pretransplant (IPS-PreHCT), and at the time of initial IPS diagnosis (IPS-Dx). In addition, control plasma samples were collected between day 14 and 21 after transplantation from allogeneic HCT recipients without complications (Control [BMT]), and from normal (nontransplantation) individuals (Control [NL]). No differences were observed between responders and nonresponders at the time of diagnosis, IPS-Dx (Resp) versus IPS-Dx (NR). In addition, plasma samples were collected at the time of study completion in those subjects that responded to therapy; n = 7 to 14 per group.
LOD indicates limit of detection; and ND, not done.
P < .01 IPS-Dx vs Control (NL), Control (BMT), and IPS-Pre Dx.
P < .01 IPS-Dx vs Control (NL) and IPS-Pre Dx only.
P < .01 IPS-Dx vs Control (NL) and Control (BMT) only.
P < .05 IPS-post (Resp) vs IPS-Dx (Resp).
P < .01 IPS-post (Resp) vs IPS-Dx (Resp).